3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Glioma
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
146
Rituximab
138
fludarabine phosphate
111
Mycophenolic Acid
69
Peripheral Blood Stem Cell Transplantation
63
fludarabine
59
Tacrolimus
58
Whole-Body Irradiation
51
venetoclax
46
Busulfan
46
ibrutinib
45
Cyclosporine
42
Lenalidomide
41
Filgrastim
41
Alemtuzumab
41
Melphalan
40
Radiotherapy
39
obinutuzumab
37
Antilymphocyte Serum
35
Etoposide
33
Methotrexate
32
ofatumumab
29
acalabrutinib
26
Bendamustine Hydrochloride
24
sargramostim
22
Methylprednisolone
18
Cytarabine
18
zanubrutinib
17
Pentostatin
17
Granulocyte Colony-Stimulating Factor
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled